Seth Wander, MD, PhD

Dr. Jason Mouabbi and Dr. Seth Wander discuss future opportunities to refine biomarker-driven treatment approaches for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss evolving questions surrounding the implementation of biomarker-guided treatment strategies in HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss practical considerations for integrating molecular testing approaches into routine care for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss real-world considerations for incorporating molecular monitoring strategies into the management of HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the practical considerations surrounding the use of ctDNA monitoring in patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Seth Wander and Dr. Jason Mouabbi discuss the potential significance of circulating tumor DNA clearance as a marker of treatment response in HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the evolving role of circulating tumor DNA dynamics as a potential tool for evaluating treatment response in HR-positive, HER2-negative advanced breast cancer.

Dr. Seth Wander and Dr. Jason Mouabbi discuss the importance of evaluating both clinical outcomes and patient experience when selecting treatment strategies for HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss emerging evidence evaluating proactive treatment strategies for patients with HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the clinical rationale for identifying and addressing ESR1-mediated endocrine resistance earlier in patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss treatment considerations for patients with HR-positive, HER2-negative advanced breast cancer who develop ESR1 mutations following first-line endocrine therapy and CDK4/6 inhibition.

Dr. Jason Mouabbi and Dr. Seth Wander discuss current approaches to biomarker testing and ESR1 mutation detection in patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss the biological role of ESR1 mutations and their impact on endocrine resistance in HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander discuss considerations for treatment selection following first-line therapy in HR-positive, HER2-negative advanced breast cancer, highlighting the evolving definition of endocrine sensitivity and the growing role of precision medicine. Dr. Wander explains how the availability of newer endocrine-based therapies and targeted treatment approaches has expanded options for patients who experience disease progression. The discussion explores how molecular alterations, including ESR1 mutations, PIK3CA mutations, AKT pathway alterations, and other biomarkers, can influence treatment selection in the second-line setting. Dr. Wander also emphasizes ongoing challenges in patients without actionable alterations or those with multiple concurrent resistance mechanisms, highlighting the need for continued research to better guide sequencing strategies. The experts underscore the increasing complexity of treatment decisions as the field moves toward more individualized approaches for patients with HR-positive, HER2-negative advanced breast cancer.

Dr. Jason Mouabbi and Dr. Seth Wander open the discussion by reviewing the evolving treatment landscape for patients with HR-positive, HER2-negative advanced breast cancer. Dr. Wander discusses the role of endocrine therapy combined with CDK4/6 inhibition as a foundational first-line treatment approach, while highlighting important patient-specific considerations such as endocrine sensitivity, prior therapy exposure, and the emergence of targeted treatment strategies. The experts discuss how advances in earlier-line therapy have improved outcomes for many patients while also contributing to an increasingly complex treatment landscape. Dr. Mouabbi emphasizes the significant impact of CDK4/6 inhibitors in transforming the management of HR-positive, HER2-negative advanced breast cancer and highlights the importance of optimizing endocrine-based treatment strategies as resistance mechanisms emerge. The discussion sets the foundation for exploring biomarker-driven approaches, including strategies aimed at addressing evolving endocrine resistance.

Experts discuss the future of breast cancer treatment, emphasizing personalized approaches and the potential of new oral therapies to improve outcomes.

Experts discuss the implications of the SERENA-6 trial, highlighting the potential benefits of early oral SERD deployment in breast cancer treatment.

Researchers analyze real-world data on ESR1-mutated breast cancer treatments, revealing promising outcomes and insights for patient care strategies.

Explore the impact of elacestrant on ESR1-mutated breast cancer, revealing real-world data insights and genomic factors influencing treatment outcomes.

Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.

Hope S. Rugo, MD, and Seth Wander, MD, PhD, discuss treatment selection after CDK4/6 inhibitor progression in advanced ER-positive breast cancer.

Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.

Seth Wander, MD, PhD, discusses how he approaches therapeutic treatment for patients with ER+ advanced breast cancer in the clinic.

Seth Wander, MD, PhD, discusses the present limitations of first- and later-line therapy for HR+ metastatic breast cancer.

Seth Wander, MD, PhD, discusses the ELAINE-1, ELAINE-2, and ELAINE-3 trials in patients with ER-positive, HER2-negative metastatic breast cancer.

Seth Wander, MD, PhD, discusses findings from an analysis of baseline genomic alterations in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who were enrolled in the single-arm, phase 2 ELAINE-2 trial of lasofoxifene plus abemaciclib.

Seth Wander, MD, PhD, discusses the evaluation of vepdegestrant (ARV-471), a proteolysis targeting chimera estrogen receptor degrader, in patients with advanced estrogen receptor/HER2-negative breast cancer.

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.